SLC7A11

Cystine/glutamate transporter · Q9UPY5 · SLC7A11 on Sugi Atlas →

8,455 patent compounds predicted against SLC7A11, 5,690 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1593568	0.88	16/20
Susalimod (SCHEMBL1229340)	1.00	5/20
Congo Red Free Acid (SCHEMBL1254806)	0.79	5/20
Congo Red Free Acid (SCHEMBL326268)	0.77	5/20
SCHEMBL1592822	0.48	5/20
SCHEMBL1228352	0.56	4/20
SCHEMBL1593252	0.49	4/20
Sulfasalazine (SCHEMBL4514)	1.00	3/20
Sulfasalazine (SCHEMBL4515)	1.00	3/20
Sulfasalazine (SCHEMBL487664)	1.00	3/20
Sulfasalazine (SCHEMBL1445288)	0.76	3/20
SCHEMBL130906	0.76	3/20
SCHEMBL586000	0.66	3/20
SCHEMBL576998	0.65	3/20
SCHEMBL497248	0.65	3/20
SCHEMBL1423903	0.56	3/20
SCHEMBL1423907	0.56	3/20
SCHEMBL608455	0.56	3/20
SCHEMBL1352720	0.55	3/20
SCHEMBL339834	0.52	3/20

Clinical trials — most relevant to SLC7A11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.	PHASE4	UNKNOWN
Cysteine Supplementation in Critically Ill Neonates	PHASE2/PHASE3	UNKNOWN
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients	PHASE2	COMPLETED
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)	PHASE1/PHASE2	COMPLETED
Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis	PHASE1/PHASE2	WITHDRAWN
A Study of Oxidative Pathways in MS Fatigue	PHASE2	COMPLETED
Stem Cell Gene Therapy for Cystinosis	PHASE1/PHASE2	COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia	PHASE2	COMPLETED
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia	PHASE2	COMPLETED
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia	PHASE2	WITHDRAWN
Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder	PHASE2	COMPLETED
DAAOI-1 Treatment for Treatment-resistant Schizophrenia	PHASE2	COMPLETED
Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD)	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels	PHASE1	COMPLETED
Open-Trial of EPI-743 for Adults With Tourette Syndrome	PHASE1	COMPLETED
Tolerability of Enteral NAC in Infants	PHASE1	NOT_YET_RECRUITING
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance	nan	COMPLETED
Kidney Transplantation in Patients With Cystinosis	nan	COMPLETED
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency	nan	NO_LONGER_AVAILABLE
Dietary Effects of Sulfur Amino Acids	nan	COMPLETED
Use of Cysteamine in the Treatment of Cystinosis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC7A11 binder may also engage these)

Protein	Name	Similarity
Q5RAG7	—	1.000	Q5RAG7 →
Q9WTR6	—	1.000	Q9WTR6 →
Q63016	—	0.997	Q63016 →
Q9Z127	—	0.996	Q9Z127 →
SLC7A5	Large neutral amino acids transporter small subunit 1	0.991	landscape →
Q8BGK6	—	0.986	Q8BGK6 →
Q7YQK4	—	0.986	Q7YQK4 →
D3ZMM8	—	0.984	D3ZMM8 →
A1L3M3	—	0.983	A1L3M3 →
Q92536	—	0.983	Q92536 →
Q9Z1K8	—	0.982	Q9Z1K8 →
Q5RKI7	—	0.981	Q5RKI7 →
Q9UM01	—	0.981	Q9UM01 →
Q3ZMH1	—	0.980	Q3ZMH1 →
Q91WN3	—	0.978	Q91WN3 →
Q8TCU3	—	0.977	Q8TCU3 →
Q9R0S5	—	0.977	Q9R0S5 →
Q49B93	—	0.977	Q49B93 →
P30823	—	0.976	P30823 →
Q28I80	—	0.976	Q28I80 →
A7MBD8	—	0.975	A7MBD8 →
Q22397	—	0.974	Q22397 →
SLC7A1	High affinity cationic amino acid transporter 1	0.974	landscape →
Q6DCE8	—	0.973	Q6DCE8 →
Q8WY07	—	0.972	Q8WY07 →
Q1EHB4	—	0.972	Q1EHB4 →
Q5PR34	—	0.971	Q5PR34 →
O64759	—	0.970	O64759 →
B3TP03	—	0.970	B3TP03 →
Q7T384	—	0.970	Q7T384 →